GTC Biotherapeutics (fka GTCB)

[exwannabe]

>> companies with interesting new technologies should not compound their risk by applying their technology to difficult or intractable targets


And perhapse that's exactly why GTCB choose not to lead with the DIC indication?

First establish ATryn as a valid biologic via the antithrombin hereditary deficiency trials, then expand to DIC; seams like the exact stratagy you would like